Clinical Trial Update: Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) [Phase 2]

View source ↗

Summary

Phase 2 trial investigating sapacitabine with cyclophosphamide and rituximab for relapsed CLL/SLL with 11q deletion; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Rituximab (rituximab)
• Sapacitabine (sapacitabine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2019-09-06